Key result
Nonrandomized patients surviving open-label titration show no difference in mortality or cardiac arrest vs placebo.
Why the study?
The patient characteristics and outcomes of Cardiac Arrhythmia Suppression Trial (CAST) participants who survived open-label drug titration without being randomized to double-blind therapy required evaluation relative to those randomized to placebo.
Does non-randomization after surviving open-label drug titration affect total mortality or resuscitated cardiac arrest compared to randomization to double-blind placebo therapy in patients from the Cardiac Arrhythmia Suppression Trial?
Observational (n=1,260)
Open-label
Does non-randomization after surviving open-label drug titration affect total mortality or resuscitated cardiac arrest compared to randomization to double-blind placebo therapy in patients from the Cardiac Arrhythmia Suppression Trial?
Although CAST patients not randomized after open-label titration had higher unadjusted mortality than placebo-randomized patients, matched comparisons showed no significant difference, while ECG events during titration and female sex strongly predicted subsequent arrhythmic death or cardiac arrest.
Answers are grounded in this paper and cite their sources.
Placebo arm event rate favors avoiding antiarrhythmic suppression; extends CAST by confirming harm in ventricular arrhythmia patients.
The patient characteristics and outcomes were studied in the 318 patients who survived open label drug titration in the Cardiac Arrhythmia Suppression Trial (CAST) and who were not randomized to double-blind therapy and in 942 patients, who were randomized to double-blind placebo therapy. The patients randomized to placebo therapy had a lower total mortality or resuscitated cardiac arrest rate (4% vs. 8.5%). However, at baseline, nonrandomized patients were dissimilar from patients randomized to placebo in the following ways: older; lower left ventricular ejection fraction; greater use of digitalis, diuretic drugs and antihypertensive agents; lesser use of beta-adrenoceptor blocking agents and more frequent prior cardiac problems, including runs of ventricular tachycardia and left bundle branch block. A matched comparison that took these inequities into account showed no significant differences in mortality or rate of resuscitation from cardiac arrest between nonrandomized patients and clinically equivalent patients randomized to placebo. Cox regression analysis indicated that two factors significantly increased the hazard ratio for arrhythmic death or resuscitated cardiac arrest in the nonrandomized patients: female gender (4.7, p less than 0.05) and electrocardiographic events (ventricular tachycardia, proarrhythmia, widened QRS complex, heart block, bradycardia) during open label titration (7.0, p less than 0.005). However, some potentially important differences between men and women were not included in the Cox regression model. Of the nonrandomized patients, approximately 70% were not randomized because of lack of suppression of ventricular premature depolarizations or adverse events, or both, and the remaining 30% because of patient or private physician request with no indication of another reason.(ABSTRACT TRUNCATED AT 250 WORDS)
No takes yet. Share an insight, caveat, or question.
Wyse et al. (1991) conducted an observational in Cardiac arrhythmia (ventricular premature depolarizations) (n=1,260). Non-randomization after surviving open-label drug titration vs. Randomization to double-blind placebo therapy was evaluated on Total mortality or resuscitated cardiac arrest. Nonrandomized patients surviving open-label titration had higher unadjusted mortality or cardiac arrest than placebo patients, with no significant difference after baseline matching.
Synapse has enriched 10 related papers. Consider them for comparative context: